This product is a synthetic antibacterial anti-tuberculosis drug that can penetrate into mycobacteria to interfere with RNA synthesis, thereby inhibiting bacterial reproduction. It is only effective against mycobacteria in the growth and reproduction period. So far, no cross-resistance has been found between this product and other anti-tuberculosis drugs.

Iron is a component of hemoglobin in red blood cells. When iron is deficient, the amount of hemoglobin synthesized by red blood cells decreases, causing the red blood cells to become smaller and their oxygen-carrying capacity to decrease, resulting in iron-deficiency anemia. Oral administration of this product can supplement iron and correct iron-deficiency anemia.

Aminoglycoside antibiotics have good antibacterial effects on Gram-negative and Gram-positive bacteria, and inhibit protein synthesis by binding to the bacterial ribosome 30S subunit.

Nicotinic acid is converted into nicotinamide in the body, and then combined with riboadenin to form nicotinamide adenine dinucleotide (coenzyme I) and nicotinamide adenine dinucleotide phosphate (coenzyme II), which are necessary for lipid amino acid, protein, purine metabolism, tissue respiration oxidation and glycogenolysis. Nicotinic acid can reduce the utilization of coenzyme A; by inhibiting the synthesis of very low density lipoprotein (VLDL), it affects the transport of cholesterol in the blood. Large doses can reduce serum cholesterol and triglyceride concentrations. Nicotinic acid has a peripheral vasodilation effect.

By inhibiting cyclooxygenase and reducing the synthesis of prostaglandins, it has anti-inflammatory, anti-rheumatic, antipyretic and analgesic effects. Its anti-inflammatory and anti-rheumatic effects are similar to those of aspirin, but its antipyretic and analgesic effects are weaker. This product has no antiplatelet aggregation effect.